# 18F ML-10 for Early Detection of Response of Brain Metastases to WBRT

> **NCT00791063** · PHASE2 · COMPLETED · sponsor: **Aposense Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Solid Tumors
- Brain Metastases

## Interventions

- **OTHER:** 18F ML-10

## Key facts

- **NCT ID:** NCT00791063
- **Lead sponsor:** Aposense Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791063, "18F ML-10 for Early Detection of Response of Brain Metastases to WBRT". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00791063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*